LY2875358 plus Erlotinib versus Erlotinib in NSCLC (JTBB)

• Research type

  Research Study

• Full title

  A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non-Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

• IRAS ID

  128245

• Contact name

  Conrad Lewanski

• Contact email

  conrad.lewanski@imperial.nhs.uk

• Sponsor organisation

  Eli Lilly and Company

• Eudract number

  2012-005476-33

• ISRCTN Number

  N/A

• REC name

  London - South East Research Ethics Committee

• REC reference

  13/LO/1121

• Date of REC Opinion

  14 Nov 2013

• REC opinion

  Further Information Favourable Opinion